AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC.

AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. | First fully AI-designed FDA approval

Key catalyst: First fully AI-designed FDA approval

Watch events: Isomorphic first FDA-approved AI-designed drug; AlphaFold 4/5 releases

Isomorphic Labs Novartis / Lilly partnerships generating preclinical candidates 2x-5x faster. Not yet at 'weeks' scale.

No propagation data yet. Run inference/.venv/bin/python scripts/ops/run_loopy_belief_propagation.py on the droplet, or wait for the Sunday 02:00 UTC weekly cron.

Beneficiaries (12)

{
  "nia": false,
  "qty": "decade → weeks",
  "mode": "FORECAST",
  "role": "Cited-CEO",
  "context": "AlphaFold 2024 Nobel Prize context; simulations over 200M proteins. Hassabis argues DC networking latency is the operative physics bottleneck for structural-biology compute.",
  "to_year": 2036,
  "conv_cues": "CEO FIRST_PERSON; explicit timeline compression",
  "direction": "HAPPEN",
  "from_year": 2026,
  "timeframe": "next 10 years (2026-2036)",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "First AI-designed drug candidate enters Phase I clinical trials",
      "source": "Isomorphic Labs roadmap: end of 2026",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.7,
      "source_url": "https://markets.financialcontent.com/stocks/article/tokenring-2026-2-2-the-biological-singularity-how-alphafold-3-is-rewriting-the-blueprint-of-drug-discovery",
      "expected_date": "2026-12-29",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2027-06-30",
        "from": "2026-06-30"
      },
      "measurement_criterion": "Isomorphic Labs, Insilico Medicine, Recursion, or peer initiates Phase I trial for a small-molecule or biologic whose discovery was primarily driven by AlphaFold/diffusion model design, registered on ClinicalTrials.gov"
    },
    {
      "kind": "llm_pre_event",
      "label": "InfiniBand / NVLink scale-up reaches single-DC fabric exceeding 100,000 GPUs per cluster",
      "source": "NVIDIA Quantum-X800; xAI Colossus 100k+",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.85,
      "source_url": "https://www.nvidia.com/en-us/data-center/dgx-gb200/",
      "expected_date": "2027-09-30",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-12-31",
        "from": "2026-06-30"
      },
      "measurement_criterion": "Public disclosure (NVIDIA earnings, customer announcement) of operational AI cluster with >=100k GPUs interconnected via Quantum-X800 InfiniBand or NVLink Switch fabric in single facility"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2027-12-18",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Drug-discovery preclinical-to-IND timeline drops below 18 months at industrial scale",
      "source": "AlphaFold 3 / Isomorphic / Recursion preclinical pipelines",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.5,
      "expected_date": "2029-03-31",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2027-06-30"
      },
      "measurement_criterion": "FDA or pharma industry reporting shows median preclinical-to-IND duration <18 months for AI-designed compounds (vs 5-7 year baseline), tracked across >=10 INDs"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -4,
      "source_id": null,
      "expected_date": "2029-12-04",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "First AI-designed therapeutic receives FDA approval",
      "source": "Insilico INS018_055 already in P2; AbCellera bnAbs",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -3,
      "source_id": null,
      "confidence": 0.45,
      "expected_date": "2030-06-30",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2032-06-30",
        "from": "2028-06-30"
      },
      "measurement_criterion": "FDA BLA or NDA approval letter explicitly identifies AI-designed origin (Isomorphic, I
... (truncated)